Biogen Inc. (BIIB) Nasdaq Global Select
302.78-10.32-3.30%
IEX real time price9:54:04 AM

News: updated – 18-Dec 09:54


Eli Lilly Moving From One End Of The Spectrum To The Other For Alzheimer’s Treatment17-Dec 08:51(SeekingAlpha)

Recently, Eli Lilly ( LLY ) announced that it had formed a partnership deal for $2 billion to get its hands on an experimental drug for treatment of Alzheimer’s disease. This deal marks for a major push for the company to develop a treatment for this neurological disease where treatment op…

Alkermes submits U.S. marketing application for diroximel fumarate for relapsing MS17-Dec 08:02(SeekingAlpha)

Alkermes plc (NASDAQ: ALKS ) has filed a New Drug Application (NDA) with the FDA seeking approval for VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Alkermes plc, Biogen Inc., Healthcare stocks news, Read more …

EMA grants Prime status for Roche’s risdiplam for SMA17-Dec 07:53(SeekingAlpha)

The European Medicines Agency grants PRIME status for Roche’s ( OTCQX:RHHBY ) risdiplam for the treatment of spinal muscular atrophy (SMA). More news on: Roche Holding Ltd ADR, PTC Therapeutics, Biogen Inc., Healthcare stocks news, Read more …

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis17-Dec 07:30(PR Newswire)

DUBLIN and CAMBRIDGE, Massachusetts , Dec. 17, 2018 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) and Biogen Inc.(Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate&#xA…